MedPath

High Dose of Dual Therapy Plus Metronidazole for Helicobacter Pylori RescueTreatment

Phase 4
Completed
Conditions
Helicobacter Pylori Infection
Interventions
Registration Number
NCT04024527
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Brief Summary

Dual therapy containing high dose of proton pump inhibitor (PPI) and amoxicillin had showed excellent eradication results with Helicobacter pylori first-line treatment. However, no study has examined the the efficacy of high dose of dual therapy or dual therapy plus metronidazole for H. pylori rescue treatment.This study is designed to evaluate the efficacy and safety of the addition of metronidazole to high dose of dual therapy for H. pylori rescue treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
306
Inclusion Criteria
  • Participants with non-ulcer functional dyspepsia or peptic ulcer disease
  • Ability and willingness to participate in the study and to sign and give informed consent
  • Confirmed H. pylori infection and with previous treatment failure
Exclusion Criteria
  • Less than 18 years old or older than 80 years
  • With previous gastric surgery
  • Major systemic diseases
  • Pregnancy or lactation
  • Allergy to any of the study drugs
  • Administration of antibiotics, bismuth,antisecretory drugs in 8 weeks prior to inclusion

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dual therapyAmoxicillinEsomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days
Metronidazole plus dual therapyMetronidazoleEsomeprazole 40mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
Dual therapyEsomeprazoleEsomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days
Metronidazole plus dual therapyEsomeprazoleEsomeprazole 40mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
Metronidazole plus dual therapyAmoxicillinEsomeprazole 40mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
Primary Outcome Measures
NameTimeMethod
Helicobacter pylori eradication rateSix weeks after completion of therapy

Six weeks after completion of therapy, H. pylori eradication was assessed by ¹³C-urea breath test. Eradication was defined as negative result from urea breath test (\<4‰) (4‰ as the cutoff value)

Secondary Outcome Measures
NameTimeMethod
Rate of adverse effectsWithin 7 days after completion of therapy

The subjects were asked to grade the severity of adverse events according to their influence on daily activities, experienced as "mild" (transient and well tolerated), "moderate" (causing discomfort and partially interfering with daily activities), or "severe" (causing considerable interference with daily activities)

Compliance rateWithin 7 days after completion of therapy

Compliance was defined as poor when they had taken less than 80% of the total medication

Trial Locations

Locations (1)

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath